KRAS G12C Mutations in NSCLC: From Target to Resistance

SIMPLE SUMMARY: A better understanding of the role of KRAS and its different mutations has led to the development of specific small-molecule inhibitors able to target KRAS G12C, an oncogenic driver mutation in a number of cancers, including non-small cell lung cancer. While these therapies hold grea...

Descripción completa

Detalles Bibliográficos
Autores principales: Addeo, Alfredo, Banna, Giuseppe Luigi, Friedlaender, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196854/
https://www.ncbi.nlm.nih.gov/pubmed/34064232
http://dx.doi.org/10.3390/cancers13112541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196854/
https://www.ncbi.nlm.nih.gov/pubmed/34064232
http://dx.doi.org/10.3390/cancers13112541

Ejemplares similares